Literature DB >> 20457188

Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors.

Vanessa de Paula Soares1, Alline Cristina Campos, Valquíria Camin de Bortoli, Hélio Zangrossi, Francisco Silveira Guimarães, Antonio Waldo Zuardi.   

Abstract

Activation of 5-HT1A receptors in the dorsal periaqueductal gray (dPAG) impairs escape behavior, suggesting a panicolytic-like effect. Cannabidiol (CBD), a major non-psychotomimetic compound present in Cannabis sativa, causes anxiolytic-like effects after intra-dPAG microinjections by activating 5-HT1A receptors. In the present work we tested the hypothesis that CBD could also impair escape responses evoked by two proposed animal models of panic: the elevated T-maze (ETM) and electric stimulation of dPAG. In experiment 1 male Wistar rats with a single cannula implanted in the dPAG received a microinjection of CBD or vehicle and, 10 min later, were submitted to the ETM and open field tests. In experiment 2 escape electrical threshold was measured in rats with chemitrodes implanted in the dPAG before and 10 min after CBD microinjection. In experiment 3 similar to experiment 2 except that the animals received a previous intra-dPAG administration of WAY-100635, a 5-HT1A receptor antagonist, before CBD treatment. In the ETM microinjection of CBD into the dPAG impaired inhibitory avoidance acquisition, an anxiolytic-like effect, and inhibited escape response, a panicolytic-like effect. The drug also increased escape electrical threshold, an effect that was prevented by WAY-100635. Together, the results suggest that CBD causes panicolytic effects in the dPAG by activating 5-HT1A receptors. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457188     DOI: 10.1016/j.bbr.2010.05.004

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  31 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.

Authors:  Brian Fiani; Kasra John Sarhadi; Marisol Soula; Atif Zafar; Syed A Quadri
Journal:  Neurol Sci       Date:  2020-06-16       Impact factor: 3.307

Review 3.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 4.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

Review 5.  Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Authors:  Ethan B Russo
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 6.  Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Authors:  Roger Hudson; Walter Rushlow; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

7.  Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats.

Authors:  Alline Cristina Campos; Vanessa de Paula Soares; Milene C Carvalho; Frederico Rogerio Ferreira; Maria Adrielle Vicente; Marcus Lira Brandão; Antonio Waldo Zuardi; Hélio Zangrossi; Francisco Silveira Guimarães
Journal:  Psychopharmacology (Berl)       Date:  2012-09-25       Impact factor: 4.530

Review 8.  Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Authors:  Alline Cristina Campos; Fabricio Araújo Moreira; Felipe Villela Gomes; Elaine Aparecida Del Bel; Francisco Silveira Guimarães
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

9.  Can marijuana make it better? Prospective effects of marijuana and temperament on risk for anxiety and depression.

Authors:  Victoria A Grunberg; Kismet A Cordova; L Cinnamon Bidwell; Tiffany A Ito
Journal:  Psychol Addict Behav       Date:  2015-09

Review 10.  Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Authors:  Natalie E Zlebnik; Joseph F Cheer
Journal:  Annu Rev Neurosci       Date:  2016-02-24       Impact factor: 12.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.